You are here

AAD

Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose

Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose

Endpoints

Flag link:

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

EP Vantage

hidradenitis suppurativa

Flag link:

AAD 2020 – Leo’s eczema wildcard proves tame

AAD 2020 – Leo’s eczema wildcard proves tame

EP Vantage

atopic dermatitis

Flag link: